BioCity backs world's first Rx to OTC switch incubator5 Sep 2019
Maxwellia considered to have the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future.
BioCity, the pioneering life science incubator and business collective, has invested in Maxwellia.
The world’s first prescription (Rx) to Over the Counter (OTC) switch incubator, Maxwellia’s novel approach converts prescription drugs into versions that can be purchased without prescription from pharmacies and supermarkets; a process known as ‘switching’.
As growing pressure and budget constraints are put upon the NHS, self-care, within therapeutics has been recognised as a future Public Health priority. Securing a GP appointment can be difficult with many not seeking treatment for manageable conditions because they do not want to ‘bother the Doctor’. The creation of new OTC products potentially enables quicker therapeutic outcomes for many, who may not previously have sought treatment. For the NHS, the shift towards self-care also supports the wider public health issues by freeing-up a GP's time.
The consumer healthcare market is currently estimated at £2.6 billion in the UK and is growing, with nearly half of all UK adults needing help to self-care for treatable conditions.
The funding round was partially completed via the BioCity angel investment platform, in which BioCity co-invests alongside a collective of business angels.
The investment will be used to support three innovative products in the areas of women’s health and healthy lifestyle that are currently in the pipeline at different stages, two of which are undergoing the approval process with the Medicines and Healthcare products Regulatory Agency (MHRA).
Maxwellia, now based at Alderley Park, is the latest graduate to have gone on to successfully secure funding from BioCity and the angel investor collective. Specialists in early-stage life science investments, BioCity has added several promising ventures to the portfolio since the beginning of the year and is quickly becoming a leading investor within the life sciences.
BioCity investment analyst, Dr Imelda Juniarsih said: "Maxwellia is spearheading the move towards self-care therapeutics; their potential impact is vast.
"By providing consumers with quicker, wider and more convenient access to medicines and reducing the burden felt by the NHS, Maxwellia could support and accelerate the move towards self-care and provide early intervention opportunities for some long-term conditions in the UK. The Maxwellia team, led by Anna Maxwell, have both the skills and the expertise to deliver and reach their goal of creating the big OTC brands of the future."
Anna Maxwell, Maxwellia CEO and founder said: "We are delighted to have the support of the BioCity fund and the benefits of their mentorship in this important phase of Maxwellia’s journey towards the commercialisation of our first approved product."
CDMOs to benefit from rising BTDs, orphan drugs and fast track status therapies
8 Nov 2019
But personalized medicines will require new logistics and manufacturing systems.Read more
Recipharm launches new service to support companies with QC and analytical requirements
1 Nov 2019
Services including method development, method validation, and stability program design and implementation.Read more
FDA approves first and only medicine in a new class of acute treatment for migraine
15 Oct 2019
The approval of Eli Lilly's Reyvow represents the first new class of acute migraine treatment approved by the FDA in more than two decades.Read more
Lonza’s Ibex solutions to support Genmab’s growing clinical portfolio
14 Oct 2019
Company's Ibex Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months.Read more
Funding to accelerate delivery of Univercells' vaccine portfolio
11 Oct 2019
European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.Read more
Industrial-scale manufacture of therapeutic exosomes
10 Oct 2019
Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.Read more
BASF and Biomillenia join forces in microbiome research to promote healthy skin
7 Oct 2019
Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.Read more
Arctoris secures funding to advance novel robotic drug discovery platform
1 Oct 2019
Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,Read more
Data on lead ADC demonstrates effective tumour regression
1 Oct 2019
IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer.Read more
Researchers develop less toxic anti-cancer drug
24 Sep 2019
New drug works like a ‘magic bullet’ that is delivered directly to the mitochondria of cancer cells.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation